Longeveron (LGVN) Other Non-Current Assets (2021 - 2026)
Longeveron (LGVN) posted quarterly Other Non-Current Assets of $18000.0 for Q1 2026, down 91.04% year-over-year from $201000.0 in Q1 2025, and down 89.77% quarter-over-quarter from $176000.0 in Q4 2025.
Longeveron (LGVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 91.04% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 91.04% YoY), while the FY2025 annual figure was $176000.0, down 12.87% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $18000.0, down from $176000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $247000.0 in Q1 2023, with the low at $18000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $200500.0 (2025), against an average of $191142.9.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets soared 37.85% in 2022, then slumped 91.04% in 2026.
- Longeveron's Other Non-Current Assets stood at $244000.0 in 2022, then declined by 20.9% to $193000.0 in 2023, then increased by 4.66% to $202000.0 in 2024, then declined by 12.87% to $176000.0 in 2025, then plunged by 89.77% to $18000.0 in 2026.
- Business Quant data shows LGVN's Other Non-Current Assets at $18000.0 in Q1 2026, $176000.0 in Q4 2025, and $178000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Dec 31, 2023 | 193,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Dec 31, 2021 | 177,000.00 |